Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimuvax maintenance after chemoradiotherapy for unresectable stage III non-small cell lung cancer
ACTRN12607000173493Phase 3Recruiting
- Sponsor
- Merck KGaA
- Start
- Dec 2006
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised trial of tecemotide and cyclophosphamide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival. Started Dec 2006; status: recruiting.
02
Drugs
tecemotidecyclophosphamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12607000173493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000173493.